D10AF51 - Clindamycin, Combinations |
Propably not porphyrinogenic |
PNP |
Important Information
Limitations: This safety classification applies only to preparations containing a combination of the drugs clindamycin, benzoylperoxide and tretinoin. The same ATC code (D10AF51) can in some countries be used for different combinations of clindamycin and other drugs, which in theory may or may not be porphyrinogenic. Please refer to the classification and monograph of each individual substance.
Rationale
Combination preparations containing clindamycin in conjunction with benzoyl peroxide or tretinoin are considered probably not porphyrinogenic due to insignificant hepatic exposure after topical application.
Chemical description
Clindamycin is a lincosamide antibiotic
Benzoylperoxide is a dibenzoyl peroxide
Tretinoin is a retinoid
Therapeutic characteristics
The combination of clindamycin and benzoylperoxide or tretinoin is used in the treatment of mild to moderate acne vulgaris. The gels are administered topically.
Hepatic exposure
After 14 consecutive days with applications of a gel containing 10 mg clindamycin and 0.25 mg tretinoin the maximal plasma concentrations were 3.5 ng/mL and 1.6 ng/mL, respectively (SPC). This is equivalent to 0.008 µM and 0.005 µM, respectively, and hepatic exposure is insignificant.
Following a four-week dosing period for clindamycin 10 mg/g and benzoyl peroxide 50 mg/g the percutaneous absorption of clindamycin was negligible (0.043 % of applied dose) (SPC).
Metabolism and pharmacokinetics
Clindamycin has been found to induce CYP3A4 in vivo and is classified probably porphyrinogenic when used systemically (for more details see monograph with ATC code: J01FF01). Clindamycin for dermal use is classified as probably not porphyrinogenic due to minimal hepatic exposure (ATC-code: D10AF01).
Benzoyl peroxide for dermal use is classified as not porphyrinogenic due to insignificant hepatic exposure (ATC-code: D10AE01).
Tretinoin for dermal use is classified as probably not porphyrinogenic due minimal percutaneous exposure (ATC-code: D10AD01).
References
- Summary of Product Characteristics
- Norwegian medicines agency. Summary of Product Characteristics (SPC). (Zalna). #1370
- The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). (Duac). #1372
- The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). (Treclin). #1371
Similar drugs
© NAPOS 2024